94109-57-6

Basic information

• Product Name: 5-aminotoluene-2-sulphonamide
• Synonyms: 5-aminotoluene-2-sulphonamide;Benzenesulfonamide, 4-amino-2-methyl- (9CI);4-Amino-2-methylbenzenesulfonamide
• CAS NO: 94109-57-6
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186.2315
• EINECS: 302-499-3
• Product Categories: SULFONAMIDE
• Mol File: 94109-57-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 168 °C
• Boiling Point: 405.1°Cat760mmHg
• Flash Point: 198.8°C
• Appearance: /
• Density: 1.359g/cm³
• Vapor Pressure: 9.01E-07mmHg at 25°C
• Refractive Index: 1.609
• PKA: 10.19±0.60(Predicted)
• CAS DataBase Reference: 5-aminotoluene-2-sulphonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aminotoluene-2-sulphonamide(94109-57-6)
• EPA Substance Registry System: 5-aminotoluene-2-sulphonamide(94109-57-6)

Safety Data

• Hazardous Substances Data: 94109-57-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H10N2O2S/c1-5-4-6(8)2-3-7(5)12(9,10)11/h2-4H,8H2,1H3,(H2,9,10,11)

Upstream product

• 62374-67-8 4-acetamino-2-methyl-benzenesulfonyl chloride 
• 537-92-8 3-Methylacetanilide 
• 5433-02-3 5(acetamido)-2-methyl-benzenesulfonamide 

Downstream Products

• 874513-73-2 2,3,4-trichloro-5,6-dinitro-toluene 
• 64063-37-2 2,6-dichloro-3-methylaniline 
• 7359-72-0 2,3,4-trichlorotoluene 
• 6324-76-1 5-benzoylamino-toluene-2-sulfonic acid amide 
• 857003-78-2 5-amino-4,6-dichloro-toluene-2-sulfonic acid amide 
• 23202-51-9 5-hydroxy-toluene-2-sulfonic acid amide 

Relevant articles and documents

TGF-beta receptor inhibitor

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compound shown as the formula (I) of the present invention is useful as a TGF-beta receptor inhibitor, particularly a TGF beta RI inhibitor, for example, in the prevention or treatment of various TGF beta RI (ALK5) mediated related diseases.

1-PHENYLPYRROLE COMPOUNDS

The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1 -C3 alkyl group; R2 represents a hydroxy -C1 -C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1 -C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like,- R5 represents a sulfamoyl group or a C1-C3 alkylsulf onyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.